Betamethasone

Rating: 3.75 - 4 review(s)
advertisement
When are you taking this medicine?

Betamethasone uses



Betamethasone Spray is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.

Betamethasone Spray is a corticosteroid indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. (1)

2 DOSAGE AND ADMINISTRATION

Shake well before use.

Apply Betamethasone Spray to the affected skin areas twice daily and rub in gently.

Use Betamethasone Spray for up to 4 weeks of treatment. Treatment beyond 4 weeks is not recommended.

Discontinue Betamethasone Spray when control is achieved.

Do not use if atrophy is present at the treatment site.

Do not bandage, cover, or wrap the treated skin area unless directed by a physician.

Avoid use on the face, scalp, axilla, groin, or other intertriginous areas.

Betamethasone Spray is for topical use only. It is not for oral, ophthalmic, or intravaginal use.

  • Apply to the affected skin areas twice daily. Rub in gently. (2)
  • Use Betamethasone Spray for up to 4 weeks and not beyond. (2)
  • Discontinue treatment when control is achieved. (2)
  • Do not use if atrophy is present at the treatment site. (2)
  • Do not use with occlusive dressings unless directed by a physician. (2)
  • Avoid use on the face, scalp, axilla, groin, or other intertriginous areas. (2)
  • Not for oral, ophthalmic, or intravaginal use. (2)
advertisement

3 DOSAGE FORMS AND STRENGTHS

Spray, 0.05% for topical use. Each gram of Betamethasone Spray contains 0.643 mg Betamethasone dipropionate USP (equivalent to 0.5 mg Betamethasone) in a slightly thickened, white to off-white oil-in-water emulsion.

Spray: 0.05% (equivalent to 0.5 mg betamethasone/g) (3)

4 CONTRAINDICATIONS

None.

  • None. (4)

5 WARNINGS AND PRECAUTIONS

  • Betamethasone Spray can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during or after treatment.
  • Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can result from systemic absorption of topical corticosteroids. (5.1)
  • Use of topical corticosteroids may require periodic evaluation for HPA axis suppression. (5.1)
  • Modify use if HPA axis suppression develops. (5.1)
  • High potency corticosteroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure and young age may predispose patients to HPA axis suppression. (5.1)
  • Pediatric patients may be more susceptible to systemic toxicity when treated with topical corticosteroids. (5.1, 8.4)

5.1 Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression and Other Unwanted Systemic Glucocorticoid Effects

Betamethasone Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during or after withdrawal of treatment. Factors that predispose to HPA axis suppression include the use of high-potency corticosteroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age.

Evaluation for HPA axis suppression may be done by using the adrenocorticotropic hormone (ACTH) stimulation test.

In a study including 48 evaluable subjects 18 years of age or older with moderate to severe plaque psoriasis, abnormal ACTH stimulation test results suggestive of adrenal suppression were identified in 5 out of 24 (20.8%) subjects after treatment with Betamethasone Spray twice daily for 15 days. No subject (0 out of 24) had abnormal ACTH stimulation test results after treatment with Betamethasone Spray twice daily for 29 days .

If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid. If signs and symptoms of steroid withdrawal occur, supplemental systemic corticosteroids may be required.

Systemic effects of topical corticosteroids may also manifest as Cushing’s syndrome, hyperglycemia, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-potency topical corticosteroids.

Minimize the unwanted risks from endocrine effects by mitigating the risk factors favoring increased systemic bioavailability and by using the product as recommended .

Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface to body mass ratios. Use of Betamethasone Spray is not recommended in pediatric patients .

5.2 Allergic Contact Dermatitis

Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation. Corroborate such an observation with appropriate diagnostic patch testing. If irritation develops, discontinue the topical corticosteroid and institute appropriate therapy.

advertisement

6 ADVERSE REACTIONS

The most common adverse reactions are application site reactions, including pruritus, burning and/or stinging, pain, and atrophy. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Promius Pharma, LLC. at 1-888-966-8766 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In two randomized, multicenter, prospective vehicle-controlled clinical trials, subjects with moderate plaque psoriasis of the body applied Betamethasone Spray or vehicle spray twice daily for 4 weeks. A total of 352 subjects applied Betamethasone Spray and 180 subjects applied vehicle spray.

Adverse reactions that occurred in at least 1% of subjects treated with Betamethasone Spray for up to 28 days are presented in Table 1.

Betamethasone Spray b.i.d.

(N=352)

Vehicle Spray b.i.d.

(N=180)

Application site pruritus 6.0% 9.4%
Application site burning

and/or stinging

4.5% 10.0%
Application site pain 2.3% 3.9%
Application site atrophy 1.1% 1.7%

Less common adverse reactions (with occurrence lower than 1% but higher than 0.1%) in subjects treated with Betamethasone spray were application site reactions including telangiectasia, dermatitis, discoloration, folliculitis and skin rash, in addition to dysgeusia and hyperglycemia. These adverse reactions were not observed in subjects treated with vehicle.

6.2 Postmarketing Experience

Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Postmarketing reports for local adverse reactions to topical corticosteroids have also included striae, irritation, dryness, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, hypertrichosis, and miliaria.

advertisement

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C

There are no adequate and well-controlled studies in pregnant women. Betamethasone Spray should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. The abnormalities observed included umbilical hernias, cephalocele, and cleft palate.

8.3 Nursing Mothers

Systemically administered corticosteroids appear in human milk and can suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids can result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Betamethasone Spray is administered to a nursing woman.

8.4 Pediatric Use

Safety and effectiveness of Betamethasone Spray in patients younger than 18 years of age have not been studied; therefore use in pediatric patients is not recommended. Because of a higher ratio of skin surface area to body mass, pediatric patients are at greater risk of systemic toxicity, including HPA axis suppression and adrenal insufficiency, when treated with topical drugs. [see Warnings and Precautions ]

Rare systemic effects such as Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients, especially those with prolonged exposure to large doses of high potency topical corticosteroids.

Local adverse reactions including skin atrophy have also been reported with use of topical corticosteroids in pediatric patients.

8.5 Geriatric Use

Clinical studies of Betamethasone Spray did not include sufficient numbers of subjects who were 65 years of age or older to determine whether they respond differently from younger subjects.

advertisement

11 DESCRIPTION

Betamethasone Spray contains 0.0643% Betamethasone dipropionate (equivalent to 0.05% Betamethasone), a synthetic, fluorinated corticosteroid.

The chemical name for Betamethasone dipropionate is 9-fluoro-11(β), 17, 21-trihydroxy-16(β)-methylpregna-1,4-diene-3,20-dione-17,21-dipropionate. The empirical formula is C28H37FO7 and the molecular weight is 504.6. The structural formula is shown below.

Each gram of Betamethasone Spray contains 0.643 mg of Betamethasone dipropionate USP (equivalent to 0.5 mg Betamethasone) in a slightly thickened, white to off-white, oil-in-water, non-sterile emulsion with the following inactive ingredients:, butylated hydroxytoluene, cetostearyl alcohol, hydroxyethyl cellulose, methylparaben, mineral oil, oleyl alcohol, polyoxyl 20 cetostearyl ether, propylparaben, purified water, and sorbitan monostearate. Betamethasone Spray is co-packaged with a manual spray pump for installation by the pharmacist prior to dispensing to patients.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of Betamethasone Spray in psoriasis is unknown.

12.2 Pharmacodynamics

Vasoconstrictor studies performed with Betamethasone Spray in healthy subjects indicate that it is in the mid-range of potency as compared with other topical corticosteroids; however, similar blanching scores do not necessarily imply therapeutic equivalence.

The potential for HPA axis suppression by Betamethasone Spray was evaluated in a study randomizing 52 adult subjects with moderate to severe plaque psoriasis. Betamethasone Spray was applied twice daily for 15 or 29 days, in subjects with psoriasis involving a mean of 29.0% and 26.5% body surface area at baseline across the 2 treatment duration arms, respectively. Forty-eight subjects were evaluated for HPA axis suppression at the end of treatment. The proportion of subjects demonstrating HPA axis suppression was 20.8% (5 out of 24) in subjects treated with Betamethasone Spray for 15 days. No subjects (0 out of 24) treated with Betamethasone Spray for 29 days had HPA axis suppression. In this study HPA axis suppression was defined as serum cortisol level ≤18 mcg/dL 30-minutes post-cosyntropin stimulation. In the 4 subjects with available follow-up values, all subjects had normal ACTH stimulation tests at follow-up.

12.3 Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids are absorbed through normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.

Plasma concentrations of Betamethasone dipropionate, betamethasone-17-propionate, and Betamethasone were measured at baseline, and before and after the last dose (1, 3, and 6 hours) in the HPA axis suppression trial in subjects with psoriasis [see Clinical Pharmacology (12.2)]. The majority of subjects had no measurable plasma concentration (<5.00 pg/mL) of Betamethasone dipropionate, while the metabolites, betamethasone-17-propionate and Betamethasone, were detected in the majority of subjects (Table 2). There was high variability in the data but there was a trend toward higher systemic exposure at Day 15 and lower systemic exposure at Day 29.

Analyte (pg/mL) Betamethasone Spray b.i.d.

(15 days)

Betamethasone Spray b.i.d.

(29 days)

Betamethasone-17-propionate 120 ± 127 63.9 ± 52.6
Betamethasone 119 ± 176 57.6 ± 55.9

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies have not been performed to evaluate the carcinogenic potential of Betamethasone dipropionate.

In a 90-day repeat-dose toxicity study in rats, topical administration of Betamethasone dipropionate spray formulation at dose concentrations of 0.05% and 0.1% (providing dose levels up to 0.5 mg/kg/day in males and 0.25 mg/kg/day in females) resulted in a toxicity profile consistent with long-term exposure to corticosteroids including reduced body weight gain, adrenal atrophy, and histological changes in bone marrow, thymus and spleen indicative of severe immune suppression. A no observable adverse effect level (NOAEL) could not be determined in this study. Although the clinical relevance of the findings in animals to humans is not clear, sustained glucocorticoid-related immune suppression may increase the risk of infection and possibly the risk of carcinogenesis.

Betamethasone was negative in the bacterial mutagenicity assay (Salmonella typhimurium and Escherichia coli), and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the in vitro human lymphocyte chromosome aberration assay, and equivocal in the in vivo mouse bone marrow micronucleus assay.

Studies in rabbits, mice, and rats using intramuscular doses up to 1, 33, and 2 mg/kg, respectively, resulted in dose-related increases in fetal resorptions in rabbits and mice.

14 CLINICAL STUDIES

Two multi-center, randomized, double-blind, vehicle-controlled clinical trials were conducted in subjects aged 18 years and older with moderate plaque psoriasis. In both trials, randomized subjects applied Betamethasone Spray or vehicle spray to the affected areas twice daily for 28 days. Enrolled subjects had body surface area of involvement between 10% to 20%, and an Investigator Global Assessment (IGA) score of 3 (moderate).

Efficacy was assessed as the proportion of subjects who were considered a treatment success (defined as having an IGA score of 0 or 1 [clear or almost clear] and at least a 2-grade reduction from baseline). Table 3 presents the efficacy results at Day 15 and Day 29.

a Treatment success is defined as an IGA of 0 or 1 (clear or almost clear) and at least a 2-grade reduction

from baseline.

Study 1 Study 2
Betamethasone Spray

b.i.d.

(N=182)

Vehicle Spray

b.i.d.

(N=95)

Betamethasone Spray

b.i.d.

(N=174)

Vehicle Spray

b.i.d.

(N=87)

Treatment Success

at Day 15

21.5% 7.4% 19.0% 2.3%
Treatment Success

at Day 29

42.7% 11.7% 34.5% 13.6%

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied/Storage

Betamethasone Spray is a slightly thickened, white to off-white, non-sterile emulsion supplied in high density polyethylene bottles with a heat induction seal lined polypropylene cap. The drug is supplied in the following volumes:

  • 60 mL
  • 120 mL (NDC 67857-808-04)

Store at controlled room temperature of 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) .

Each unit is co-packaged with a manual spray pump for installation by the pharmacist prior to dispensing.

16.2 Handling/Instructions for the Pharmacist

  • Remove the spray pump from the wrapper.
  • Remove and discard the cap from the bottle.
  • Keeping the bottle upright, insert the spray pump into the bottle and turn clockwise until it is closed tightly.
  • Dispense the bottle with the spray pump inserted.
  • Include the date dispensed in the space provided on the carton.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Inform patients of the following:

  • Discontinue therapy when control is achieved, unless directed otherwise by the physician.
  • Do not use for longer than 4 consecutive weeks.
  • Avoid contact with the eyes.
  • Avoid use of Betamethasone Spray on the face, scalp, underarms, groin or other intertriginous areas, unless directed by the physician.
  • Do not occlude the treatment area with bandage or other covering, unless directed by the physician.
  • Local reactions and skin atrophy are more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids.

Manufactured by: DPT Laboratories, Ltd., San Antonio, TX 78215

Distributed by: Promius Pharma, LLC., Princeton, NJ 08540

Betamethasone is a trademark of Promius Pharma, LLC.

Issued: 02/2016

007465

140728

This Patient Information has been approved by the U.S. Food and Drug Administration Issued: 02/2016
PATIENT INFORMATION

Betamethasone (ser-ne-vo)

(betamethasone dipropionate)

Spray, 0.05%

Important: Betamethasone Spray is for use on the skin only. Do not get Betamethasone Spray near or in your eyes, mouth, or vagina.

What is Betamethasone Spray?

  • Betamethasone Spray is a prescription corticosteroid medicine used to treat mild to moderate plaque psoriasis in people 18 years of age and older.

It is not known if Betamethasone Spray is safe and effective in children under 18 years of age. Betamethasone Spray is not recommended for use in patients under 18 years of age.


Before you use Betamethasone Spray, tell your doctor about all of your medical conditions, including if you:

  • are allergic to any of the ingredients in Betamethasone Spray. See the end of this leaflet for a list of the ingredients in Betamethasone Spray.
  • have thinning of the skin (atrophy) at the treatment site
  • are pregnant or plan to become pregnant. It is not known if Betamethasone Spray will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if Betamethasone Spray passes into breast milk.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your doctor if you take other corticosteroid medicines by mouth or use other products on your skin that contain corticosteroids.


How should I use Betamethasone Spray?

See the “Instructions for Use” for detailed information about the right way to apply Betamethasone Spray.

  • Use Betamethasone Spray exactly as your doctor tells you to use it.
  • Your doctor should tell you how much Betamethasone Spray to use and where to apply it.
  • Apply Betamethasone Spray 2 times a day.
  • Use Betamethasone Spray for the shortest amount of time needed to treat your plaque psoriasis. Tell your doctor if your skin condition is not getting better after 4 weeks of using Betamethasone Spray. Do not use Betamethasone Spray for longer than 4 weeks.
  • Wash your hands after applying Betamethasone Spray.
  • Do not use Betamethasone Spray on your face, scalp, underarms (armpits), groin, or areas where your skin may touch or rub together.
  • Do not bandage, cover, or wrap the treated skin area, unless your doctor tells you to.

What are the possible side effects of Betamethasone Spray?

  • Betamethasone Spray can pass through your skin. Too much Betamethasone Spray passing through your skin can cause your adrenal glands to stop working. Your doctor may do blood tests to check for adrenal gland problems.

The most common side effects of Betamethasone Spray include itching, burning, stinging, pain, and thinning of skin (atrophy) at the treated site.

These are not all the possible side effects of Betamethasone Spray.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


How should I store Betamethasone Spray?

  • Store Betamethasone Spray at room temperature between 68°F to 77°F (20°C to 25°C)
  • Throw away (discard) any unused Betamethasone Spray after 4 weeks.

Keep Betamethasone Spray and all medicines out of the reach of children.


General information about the safe and effective use of Betamethasone Spray.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Betamethasone Spray for a condition for which it was not prescribed. Do not give Betamethasone Spray to other people even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or doctor for information about Betamethasone Spray that is written for health professionals.


What are the ingredients in Betamethasone Spray?

Active ingredient: Betamethasone dipropionate

Inactive ingredients: butylated hydroxytoluene, cetostearyl alcohol, hydroxyethyl cellulose, methylparaben, mineral oil, oleyl alcohol, polyoxyl 20 cetostearyl ether, propylparaben, purified water, and sorbitan monostearate

Manufactured by: DPT Laboratories, Ltd., San Antonio, TX 78215

Distributed by: Promius Pharma, LLC., Princeton, NJ 08540

007465

140728


Instructions for Use

Betamethasone (ser-ne-vo)

(betamethasone dipropionate)

Spray, 0.05%

Important: Betamethasone Spray is for use on the skin only. Do not get Betamethasone Spray near or in your eyes, mouth, or vagina.

Read this “Instructions for Use” before you start using Betamethasone Spray and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment.

Parts of the Betamethasone Spray bottle.

Figure A

How to apply Betamethasone Spray:

Step 1: Shake the Betamethasone Spray bottle well. Remove the cap from the pump top.

Step 2: Hold the bottle in an upright position while pointing the opening of the pump top in the direction of the affected area. To spray, push down on the pump top. Apply Betamethasone Spray to the affected area as instructed by your doctor. (See Figure B )

Figure B

Step 3: Spray only enough Betamethasone Spray to cover the affected area, for example, the elbow (See Figure C ). Rub in Betamethasone Spray gently.

Figure C

Repeat Steps 2 and 3 to apply Betamethasone Spray to other affected areas as instructed by your doctor.

Step 4: After applying Betamethasone Spray, place the cap back onto the pump top. (See Figure D )

Figure D

How should I store Betamethasone Spray?

  • Store Betamethasone Spray at room temperature between 68°F to 77°F (20°C to 25°C).
  • Throw away (discard) any unused Betamethasone Spray after 28 days.

Keep Betamethasone Spray and all medicines out of the reach of children.

This “Instructions for Use” has been approved by the U.S. Food and Drug Administration.

Manufactured by: DPT Laboratories, Ltd., San Antonio, TX 78215

Distributed by: Promius Pharma, LLC., Princeton, NJ 08540

Betamethasone is a trademark of Promius Pharma, LLC.

Issued: 02/2016

007528

140693

Betamethasone pharmaceutical active ingredients containing related brand and generic drugs:

Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.


Betamethasone available forms, composition, doses:

Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.

Price
Beta-Val 0.1% Cream 15 gm Tube11.99 USD
Beta-Val 0.1% Cream 45 gm Tube12.99 USD
Beta-Val 0.1% Lotion 60ml Bottle14.99 USD
Beta-val 0.1% cream0.32 USD
Betaderm Mild 0.05 % Cream0.06 USD
Betaderm Mild 0.05 % Ointment0.07 USD
Betaderm Regular 0.1 % Cream0.09 USD
Betaderm Regular 0.1 % Ointment0.1 USD
Betamethasone Dipropionate 0.05% Cream 15 gm Tube12.99 USD
Betamethasone Dipropionate 0.05% Cream 45 gm Tube18.9 USD
Betamethasone Dipropionate 0.05% Lotion 60ml Bottle40.4 USD
Betamethasone Dipropionate 0.05% Ointment 15 gm Tube13.51 USD
Betamethasone Dipropionate 0.05% Ointment 45 gm Tube19.67 USD
Betamethasone Dipropionate Aug 0.05% Cream 15 gm Tube39.62 USD
Betamethasone Dipropionate Aug 0.05% Cream 50 gm Tube88.66 USD
Betamethasone Dipropionate Aug 0.05% Gel 15 gm Tube39.46 USD
Betamethasone Dipropionate Aug 0.05% Gel 50 gm Tube88.26 USD
Betamethasone Dipropionate Aug 0.05% Lotion 60ml Bottle100.64 USD
Betamethasone Dipropionate Aug 0.05% Ointment 15 gm Tube58.83 USD
Betamethasone Dipropionate Aug 0.05% Ointment 45 gm Tube118.42 USD
Betamethasone Valerate 0.1% Cream 15 gm Tube11.99 USD
Betamethasone Valerate 0.1% Cream 45 gm Tube12.99 USD
Betamethasone Valerate 0.1% Lotion 60ml Bottle16.99 USD
Betamethasone Valerate 0.1% Ointment 15 gm Tube11.99 USD
Betamethasone Valerate 0.1% Ointment 45 gm Tube15.87 USD
Betamethasone ac-sp 6 mg/ml vial7.68 USD
Betamethasone acetate powd78.03 USD
Betamethasone dp aug 0.05% crm2.17 USD
Betamethasone dp powder48.96 USD
Betamethasone sod phos powder56.61 USD
Betamethasone va 0.1% cream0.14 USD
Betamethasone valerate powd47.89 USD
Betnesol (5 mg/100Ml) 5 mg/enm Enema9.51 USD
Celestone soluspan 6 mg/ml8.08 USD
Cream; Topical; Betamethasone 0.1%
Cream; Topical; Betamethasone 0.2%
Diprolene 0.05% Gel 15 gm Tube49.99 USD
Diprolene 0.05% Gel 50 gm Tube103.99 USD
Diprolene 0.05% Lotion 30ml Bottle78.79 USD
Diprolene 0.05% Lotion 60ml Bottle148.19 USD
Diprolene 0.05% Ointment 15 gm Tube69.38 USD
Diprolene 0.05% Ointment 50 gm Tube147.41 USD
Diprolene AF 0.05% Cream 15 gm Tube69.38 USD
Diprolene AF 0.05% Cream 50 gm Tube147.02 USD
Diprolene Glycol 0.05 % Glycol Cream0.54 USD
Diprolene Glycol 0.05 % Glycol Lotion0.49 USD
Diprolene Glycol 0.05 % Glycol Ointment0.54 USD
Diprolene af 0.05% cream4.19 USD
Diprosone 0.05 % Cream0.21 USD
Diprosone 0.05 % Lotion0.21 USD
Diprosone 0.05 % Ointment0.23 USD
Lotrisone 1-0.05% Lotion2.89 USD
Lotrisone cream2.71 USD
Luxiq 0.12% Foam 100 gm Can325.17 USD
Luxiq 0.12% Foam 50 gm Can174.7 USD
Luxiq 0.12% foam5.01 USD
Maxivate 0.05% Cream 45 gm Tube44.99 USD
Prevex B 0.1 % Occlusive Cream0.4 USD
Ratio-Ectosone Mild 0.05 % Cream0.06 USD
Ratio-Ectosone Mild 0.05 % Lotion0.23 USD
Ratio-Ectosone Regular 0.1 % Cream0.1 USD
Ratio-Ectosone Regular 0.1 % Lotion0.3 USD
Ratio-Ectosone Scalp 0.1 % Lotion0.09 USD
Ratio-Topilene 0.05 % Glycol Cream0.54 USD
Ratio-Topilene 0.05 % Glycol Lotion0.49 USD
Ratio-Topilene 0.05 % Glycol Ointment0.54 USD
Ratio-Topisone 0.05 % Cream0.21 USD
Ratio-Topisone 0.05 % Lotion0.21 USD
Ratio-Topisone 0.05 % Ointment0.23 USD
Solution; Oral; Betamethasone 0.05%
Tablets, Dispersible; Oral; Betamethasone 2 mg
Tablets; Oral; Betamethasone 0.5 mg
Valisone Scalp 0.1 % Lotion0.1 USD

Betamethasone destination | category:

Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.


Betamethasone Anatomical Therapeutic Chemical codes:

A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.


Betamethasone pharmaceutical companies:

Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.


advertisement

References

  1. Dailymed."BETAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. "betamethasone". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  3. "betamethasone". http://www.drugbank.ca/drugs/DB0044... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Betamethasone?

Depending on the reaction of the Betamethasone after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Betamethasone not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Betamethasone addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Betamethasone, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Betamethasone consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Two visitors reported useful

How is the drug Betamethasone useful in reducing or relieving the symptoms? How useful is it?
According to the survey conducted by the website sdrugs.com, there are variable results and below are the percentages of the users that say the medicine is useful to them and that say it is not helping them much. It is not ideal to continue taking the medication if you feel it is not helping you much. Contact your healthcare provider to check if there is a need to change the medicine or if there is a need to re-evaluate your condition. The usefulness of the medicine may vary from patient to patient, depending on the other diseases he is suffering from and slightly depends on the brand name.
Visitors%
Useful2
100.0%

One visitor reported side effects

Did you get side effects while taking the Betamethasone drug, or were there no side effects?
According to the survey conducted by website sdrugs.com users, the below-mentioned percentages indicate the number of people experiencing the side effects and the number of people not experiencing the side effects when taking Betamethasone medicine. Every drug produces minimal side effects, and they are negligible most times, when compared to the desired effect [use] of the medicine. Side effects depend on the dose you are taking, any drug interactions that happen when you are on other medications, if the patient is sensitive, and other associated conditions. If you cannot tolerate the side effects, consult your doctor immediately, so he can either adjust the dose or change the medication.
Visitors%
It has side effects1
100.0%

One visitor reported price estimates

What is your opinion about drug cost? Did you feel the cost is apt, or did you feel it is expensive?
The report given by the sdrugs.com website users shows the following figures about several people who felt the medicine Betamethasone is expensive, and the medicine is not expensive. The results are mixed. The perception of the cost of the medicine to be expensive or not depends on the brand name of the medicine, country, and place where it is sold, and the affordability of the patient. You can choose a generic drug in the place of the branded drug to save the cost. The efficiency of the medicine will not vary if it is generic or a branded one.
Visitors%
Not expensive1
100.0%

Two visitors reported frequency of use

How often in a day do you take the medicine?
Are you taking the Betamethasone drug as prescribed by the doctor?

Few medications can be taken Once in a day more than prescribed when the doctor's advice mentions the medicine can be taken according to frequency or severity of symptoms. Most times, be very careful and clear about the number of times you are taking the medication. The report of sdrugs.com website users about the frequency of taking the drug Betamethasone is mentioned below.
Visitors%
Once in a day2
100.0%

Elenen visitors reported doses

What is the dose of Betamethasone drug you are taking?
According to the survey conducted among sdrugs.com website users, the maximum number of people are using the following dose 1-5mg. Few medications come in only one or two doses. Few are specific for adult dose and child dose. The dose of the medicine given to the patient depends on the severity of the symptom/disease. There can be dose adjustments made by the doctor, based on the progression of the disease. Follow-up is important.
Visitors%
1-5mg6
54.5%
6-10mg3
27.3%
11-50mg2
18.2%

Three visitors reported time for results

What is the time duration Betamethasone drug must be taken for it to be effective or for it to reduce the symptoms?
Most chronic conditions need at least some time so the dose and the drug action gets adjusted to the body to get the desired effect. The stastistics say sdrugs.com website users needed 1 week to notice the result from using Betamethasone drug. The time needed to show improvement in health condition after using the medicine Betamethasone need not be same for all the users. It varies based on other factors.
Visitors%
1 week2
66.7%
1 month1
33.3%

Three visitors reported administration

The drugs are administered in various routes, like oral or injection form. They are administered before food or after food. How are you taking Betamethasone drug, before food or after food?
Click here to find out how other users of our website are taking it. For any doubts or queries on how and when the medicine is administered, contact your health care provider immediately.
Visitors%
After food1
33.3%
Empty stomach1
33.3%
With a meal1
33.3%

Five visitors reported age

Visitors%
> 602
40.0%
30-451
20.0%
16-291
20.0%
46-601
20.0%

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 26 here

The information was verified by Dr. Arunabha Ray, MD Pharmacology

© 2002 - 2020 "sdrugs.com". All Rights Reserved